MedTrace Logo

Warfarine in Unexplained Oligohydramnios

NCT01569035 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2021-01-07

No results posted yet for this study

Summary

This study examines using oral anti coagulant warfarin in the management of unexplained oligohydramnios improve the perinatal outcome with little or no complications to the mother or the neonates.

Conditions

  • Oligohydramnios

Interventions

DRUG

warfarin

3 mg warfarin oral tablet for 2 to 3 weeks

Sponsors & Collaborators

  • Woman's Health University Hospital, Egypt

    lead OTHER

Principal Investigators

  • Alaa M Ismail, M.D · Women Health Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2011-07-31
Completion
2011-07-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01569035 on ClinicalTrials.gov